Stock Research: Dr. Reddy's

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Dr. Reddy's

BSE:500124 INE089A01023
19
  • Value
    52
  • Growth
    11
  • Safety
    Safety
    65
  • Combined
    28
  • Sentiment
    34
  • 360° View
    360° View
    19
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. It operates in the pharmaceutical industry, specializing in APIs, generics, branded generics, biosimilars, and OTC pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. In the last fiscal year, the company had a market cap of $12,191 million, profits of $2,558 million, and revenue of $3,820 million, with 26944 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 19 (better than 19% compared with alternatives), overall professional sentiment and financial characteristics for the stock Dr. Reddy's are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Dr. Reddy's. The consolidated Value Rank has an attractive rank of 65, which means that the share price of Dr. Reddy's is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 65% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 52. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 34. Professional investors are more confident in 66% other stocks. The consolidated Growth Rank also has a low rank of 11, which means that the company is below average in terms of growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. 89 of its competitors have better growth. ...read more

more
Index
Good Governace Growth Markets
Independent Boards Growth Markets
Low Waste
Recycling
CNX Nifty 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
65 65 63 61
Growth
11 13 31 47
Safety
Safety
52 51 59 47
Sentiment
34 43 84 50
360° View
360° View
19 25 76 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
21 21 38 83
Opinions Change
23 10 39 50
Pro Holdings
n/a 54 99 8
Market Pulse
71 88 77 57
Sentiment
34 43 84 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
65 65 63 61
Growth
11 13 31 47
Safety Safety
52 51 59 47
Combined
28 21 53 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
71 75 82 63
Price vs. Earnings (P/E)
62 56 62 61
Price vs. Book (P/B)
62 57 62 58
Dividend Yield
45 42 37 42
Value
65 65 63 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
8 48 17 46
Profit Growth
21 25 51 86
Capital Growth
38 1 46 42
Stock Returns
49 43 67 21
Growth
11 13 31 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
49 56 60 44
Refinancing
76 72 74 66
Liquidity
44 46 52 47
Safety Safety
52 51 59 47

Similar Stocks

Discover high‑ranked alternatives to Dr. Reddy's and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.